TL;DR
This systematic review explores the potential of 68Ga-Pentixafor PET as a novel imaging agent for atherosclerosis, finding it offers superior lesion detection and uptake compared to the current standard, 18F-FDG PET. The study also highlights a significant correlation between 68Ga-Pentixafor uptake, cardiovascular risk factors, and plaque calcification, suggesting its promise for identifying vulnerable plaques.
What Problem Does This Paper Address?
Atherosclerosis, a chronic inflammatory disease, is the underlying cause of many cardiovascular diseases and a leading cause of death. While 18F-FDG PET is currently used to image plaque inflammation, its clinical utility is limited by high background uptake in normal tissues like the myocardium and neck, making it difficult to accurately assess coronary artery inflammation. This necessitates the development of more specific PET tracers. 68Ga-Pentixafor, a novel tracer targeting the chemokine receptor type 4 (CXCR4) overexpressed on inflammatory cells, shows promise for identifying high-risk atherosclerotic plaques. This paper addresses the need for a comprehensive understanding of 68Ga-Pentixafor PET's imaging capabilities and clinical relevance in atherosclerosis by systematically reviewing existing evidence.
Methods
The authors conducted a systematic literature search of PubMed and Embase databases for studies evaluating 68Ga-Pentixafor PET in atherosclerosis, with a timeframe up to December 2022. They followed PRISMA guidelines for systematic reviews. The quality of included studies was assessed using the QUADAS-2 tool. Data extraction focused on imaging outcomes (lesion detection, tracer uptake, agreement with 18F-FDG PET) and clinical correlations (with cardiovascular risk factors and plaque calcification). Due to clinical heterogeneity, a qualitative synthesis and descriptive analysis of the findings were performed rather than a meta-analysis.
Datasets
Not discussed in the paper. The paper is a systematic review of existing studies, not a study that collected new data.
Key Insights and Ideas
- Superiority of 68Ga-Pentixafor: The review consistently points to 68Ga-Pentixafor PET demonstrating better imaging results than 18F-FDG PET, detecting more lesions and showing higher tracer uptake. This suggests it could potentially overcome some limitations of 18F-FDG PET.
- CXCR4 as a Target: The underlying mechanism of 68Ga-Pentixafor targeting CXCR4 on inflammatory cells is crucial for its specificity in identifying active atherosclerotic lesions.
- Clinical Correlation is Key: The strong correlation found between 68Ga-Pentixafor uptake, cardiovascular risk factors (like hypertension, diabetes, smoking), and plaque calcification is a significant finding. This suggests the tracer can provide clinically relevant information beyond just lesion detection.
- Potential for Vulnerable Plaque Identification: The ability to correlate tracer uptake with risk factors and calcification hints at the potential of 68Ga-Pentixafor PET to identify "vulnerable plaques" that are more prone to rupture and adverse events.
- Future Replacement for 18F-FDG PET? The findings suggest that 68Ga-Pentixafor PET is a promising modality that may eventually replace 18F-FDG PET for atherosclerosis imaging, offering improved specificity and potentially better quantification.
Key Results
- Lesion Detection: 68Ga-Pentixafor PET detected significantly more atherosclerotic lesions than 18F-FDG PET (e.g., 88% vs. 48% in one study).
- Tracer Uptake (TBR): Mean target-to-background ratios (TBR) for 68Ga-Pentixafor PET were consistently higher than for 18F-FDG PET across multiple studies, indicating greater tracer accumulation in atherosclerotic lesions. For instance, one study reported a TBR of 1.90± vs. 1.63±0.29 for 68Ga-Pentixafor vs. 18F-FDG PET, respectively.
- Correlation with Risk Factors: Higher 68Ga-Pentixafor uptake was observed in patients with a higher burden of cardiovascular risk factors. For example, one study found significantly increased TBR in a high-risk group compared to a low-risk group (1.9±0.3 vs. 1.7±0.2, p<0.05).
- Correlation with Plaque Calcification: An inverse relationship was noted between tracer uptake and the degree of plaque calcification, with non-calcified lesions showing the highest uptake.
- Agreement: Good agreement was found between the two imaging modalities, particularly for early scans.
Limitations and Future Work
The authors acknowledge several limitations:
- Novelty of Tracer: 68Ga-Pentixafor is a relatively new tracer, leading to a limited number of available studies (n=6) for this review.
- Study Overlap: Some studies were conducted by the same research groups, raising the possibility of patient data overlap.
- Population Heterogeneity: The included studies involved diverse patient populations, which could contribute to heterogeneity in the results.
- Variability in TBR Definitions: The criteria for defining positive atherosclerotic lesions based on TBR varied across studies.
- Descriptive Analysis: Due to clinical heterogeneity, only a descriptive analysis was performed, limiting the ability to draw definitive quantitative conclusions.
Future work should focus on:
- Larger Prospective Studies: More prospective, randomized studies are needed to further validate the clinical utility of 68Ga-Pentixafor PET.
- Standardized Protocols: Developing standardized imaging protocols and quantitative methods is crucial for improving vascular quantification and comparability across studies.
- Further Elucidating Mechanisms: Deeper understanding of the biological mechanisms of CXCR4 could enhance the clinical application of this tracer.
- Addressing Resolution Limits: Further research is needed to overcome the challenges of accurately estimating tracer uptake in small vascular lesions due to PET's spatial resolution limitations.
Summary updated